AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as AP5346 and oxaliplatin, work in different ways
to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing.
PURPOSE: This randomized clinical trial is studying the dose of AP5346 to see how well it
works compared with the dose of oxaliplatin in treating patients with metastatic and/or
unresectable recurrent head and neck cancer.